The price of Coherus BioSciences Inc. (NASDAQ:CHRS) shares last traded on Wall Street rose 0.45% to $4.42.
CHRS stock price is now -3.04% away from the 50-day moving average and -35.92% away from the 200-day moving average. The market capitalization of the company currently stands at $405.71M.
With the price target of $12, Citigroup recently initiated with Buy rating for Coherus BioSciences Inc. (NASDAQ: CHRS).
A total of 1.88% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CHRS stock. A new stake in Coherus BioSciences Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $2,532,000. CAXTON ASSOCIATES LP invested $496,000 in shares of CHRS during the first quarter. In the first quarter, PROFUND ADVISORS LLC acquired a new stake in Coherus BioSciences Inc. valued at approximately $341,000. NEW YORK LIFE INVESTMENT MANAGEMENT LLC acquired a new stake in CHRS for approximately $322,000. ENDURANT CAPITAL MANAGEMENT LP purchased a new stake in CHRS valued at around $287,000 in the second quarter.
A candlestick chart of Coherus BioSciences Inc. (NASDAQ: CHRS) showed a price of $4.4000 on Tuesday morning. During the past 12 months, Coherus BioSciences Inc. has had a low of $3.60 and a high of $14.11. The fifty day moving average price for CHRS is $4.5586 and a two-hundred day moving average price translates $6.8974 for the stock.
The latest earnings results from Coherus BioSciences Inc. (NASDAQ: CHRS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.75, missing analysts’ expectations of -$0.57 by -0.18. This compares to -$1.24 EPS in the same period last year. The company reported revenue of $32.44 million for the quarter, compared to $60.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -46.04 percent. For the current quarter, analysts expect CHRS to generate $53.92M in revenue.
Coherus BioSciences Inc.(CHRS) Company Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
